REVIEW  HEPATOBILIARY IMAGING 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2024 December;68(4):270-87

DOI: 10.23736/S1824-4785.24.03572-6

Copyright © 2024 EDIZIONI MINERVA MEDICA

language: English

Radioembolization of HCC and secondary hepatic tumors: a comprehensive review

Ahmad ARAR ¹ ✉, Alex HEGLIN ², Shriya VELURI ³, Mhd Wisam ALNABLSI ¹, Jamaal L. BENJAMIN ¹, Moaz CHOUDHARY ¹, Anil PILLAI ¹

¹ Division of Interventional Radiology, Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA; ² Division of Nuclear Medicine, Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA; ³ The University of Texas Health Science Center, San Antonio, TX, USA

Transarterial radioembolization (TARE), also called Selective Internal Radiation Therapy (SIRT), has emerged as an effective locoregional therapy for primary and secondary hepatic tumors, utilizing yttrium-90 (Y90) microspheres and other agents such as holmium-166 and rhenium-188. TARE has various applications in the management of HCC across different BCLC stages. Radiation segmentectomy, which involves administering high doses of Y90 (>190 Gy), can be both curative and ablative, achieving complete necrosis of the tumor. In contrast, radiation lobectomy involves administering a lower dose of Y90 (80-120 Gy) as a neoadjuvant treatment modality to improve local control and induce future liver remnant (FLR) hypertrophy in patients who are planned to undergo surgery but have insufficient FLR. Modified radiation lobectomy combines both techniques and offers several advantages over portal vein embolization (PVE). Y90 is also used in downstaging HCC patients outside liver transplantation criteria, as well as bridging those awaiting liver transplantation (LT). Multiple studies and combined analyses were described to highlight the outcomes of TARE and compare it with other treatment modalities, including TACE and sorafenib. Additionally, the review delves into the efficacy and safety of radioembolization in managing metastatic colorectal cancer and other metastatic tumors to the liver. Recent studies have emphasized the role of personalized dosimetry for improved outcomes, and thus we described the different methods used for this purpose. Pretherapy imaging, estimating lung shunt, selection of therapeutic radionuclides, adverse effects, and cost-effectiveness were all discussed as well.

KEY WORDS: Hepatocellular carcinoma; Therapeutic embolization; Liver neoplasms